Holen Sie sich die Stockscreener-App
89.73
1.21%
-1.055
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$90.79
Offen:
$90.78
24-Stunden-Volumen:
6.21M
Relative Volume:
0.53
Marktkapitalisierung:
$155.89B
Einnahmen:
$45.13B
Nettoeinkommen (Verlust:
$6.28B
KGV:
25.00
EPS:
3.5895
Netto-Cashflow:
$7.38B
1W Leistung:
-1.58%
1M Leistung:
-12.39%
6M Leistung:
-27.45%
1J Leistung:
-31.47%
1-Tages-Spanne:
$89.14
$90.90
1-Wochen-Bereich:
$89.14
$94.79
52-Wochen-Spanne:
$89.14
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
89.71 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
300.86 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.38 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.16 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.07 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
AI Models Split on Abbott Laboratories (ABT) as Fundamentals Clash With Technical and Valuation Concerns - TipRanks
Abbott Laboratories (ABT) Receives FDA Clearance and CE Mark for Next-Generation Ultreon™ 3.0 Software - Yahoo Finance
Abbott–Exact Sciences, BioMarin–Amicus among deals cleared in Japan in Q1 - MLex
How Investors Are Reacting To Abbott (ABT) Gaining FDA, CE Clearance For AI-Guided Ultreon 3.0 - Yahoo Finance
Abbott Laboratories stock hits 52-week low at $90.72 - Investing.com
Abbott Laboratories stock hits 52-week low at $90.72 By Investing.com - Investing.com Australia
FDA Reports Baby Formula Safety, Highlights Abbott (ABT) Among C - GuruFocus
Abbott Receives FDA Clearance, CE Mark for Ultreon 3.0 AI Imaging Platform - AIM Media House
ABT SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
FDA search for baby formula contamination finds little - Crain's Chicago Business
Abbott Laboratories (ABT) EVP reports 5,314-share trust move - Stock Titan
Ultreon 3.0 regulatory milestone sees Abbott Laboratories stock down 2.64% amid oversold conditions - Traders Union
[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Lawsuit Claims Abbott, Boston Scientific SCS Pre-Market Approval Supplements Caused Permanent Injuries - AboutLawsuits.com
Fund Update: 1,400,797 ABBOTT LABORATORIES (ABT) shares added to FLOSSBACH VON STORCH SE portfolio - Quiver Quantitative
symbol__ Stock Quote Price and Forecast - CNN
Abbott Laboratories Stock: Why Analysts Rate a Buy in 2026 - TIKR.com
Abbott’s Ultreon 3.0 AI Imaging Clearance And What It Means For Valuation - simplywall.st
Abbott’s FDA-Cleared Ultreon 3.0 Redefines Imaging in Coronary Interventions - The Indian Practitioner
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott By Investing.com - Investing.com Canada
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott - Investing.com
Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1 - Yahoo Finance
Middle East and Africa Continuous Glucose Monitoring Market Forecast and Company Analysis Report 2026-2034 Featuring Dexcom, Medtronic, Senseonics, Abbott Diabetes Care, and GlySens - GlobeNewswire Inc.
Major Insider Move Signals Growing Confidence at Abbott Laboratories - TipRanks
Abbott (NYSE: ABT) awards director 2,286 restricted stock units - Stock Titan
Kevin Conroy (ABBOTT LABORATORIES: ABT) reports 131,451-share Form 3 holding - Stock Titan
Abbott Laboratories director Daniel Starks buys $926,537 in shares - Investing.com
Abbott Laboratories director Daniel Starks buys $926,537 in shares By Investing.com - Investing.com India
[Form 4] ABBOTT LABORATORIES Insider Trading Activity - Stock Titan
Abbott Laboratories (NYSE: ABT) director receives 2,286-share restricted stock unit award - Stock Titan
Abbott Laboratories (ABT) director gets RSU and option awards - Stock Titan
Abbott Laboratories (NYSE: ABT) grants shares and stock options to director - Stock Titan
Abbott (NYSE: ABT) director Darren McDew receives 2,286-share RSU award - Stock Titan
Abbott Laboratories (NYSE: ABT) director gets 2,286-share stock unit grant - Stock Titan
Director at Abbott Laboratories (NYSE: ABT) awarded 2,286 share-linked units - Stock Titan
Abbott Laboratories (NYSE: ABT) grants director 2,286 RSUs - Stock Titan
Director at Abbott Laboratories (NYSE: ABT) receives 2,286-share stock grant - Stock Titan
Abbott Laboratories stock (US0028241000): Why Google Discover changes matter more now - AD HOC NEWS
Abbott Laboratories (NYSE: ABT) director awarded 2,286 RSUs - Stock Titan
Steady action for Abbott Laboratories stock as price tests resistance levels near $93.37 - Traders Union
Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Exact Sciences Acquisition - Quiver Quantitative
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report - GlobeNewswire
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report 2025-2034 Featuring Roche, Danaher, Abbott Laboratories, Thermo Fischer Scientific, Bio-Rad Laboratories, Sysmex, BD & Co, and Biomerieux - Yahoo Finance
Abbott gains FDA clearance, CE mark approval for AI-powered imaging platform - Cardiovascular Business
Abbott (ABT) Gains FDA and CE Approval for Ultreon 3.0 Software - GuruFocus
How to Pick a Healthcare Stock That Can Weather Any Market - The Globe and Mail
HbA1c Analyzer Market to Reach USD 1.6 Billion in 2026, Led - openPR.com
Abbott receives FDA clearance, CE Mark for AI imaging platform By Investing.com - Investing.com Canada
Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform - Abbott MediaRoom
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.51%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):